Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds
An early study suggests that a common asthma drug may help treat hard-to-manage cancers, including aggressive breast cancers. The research indicates that blocking a specific protein could enhance the effectiveness of cancer immunotherapy. If confirmed, this finding could provide new options for patients resistant to current treatments.
- ▪The study focuses on the protein cysteinyl leukotriene receptor 1 (CysLTR1), which tumors may exploit to weaken immune responses.
- ▪Montelukast, an existing asthma medication, can block CysLTR1 and potentially reprogram immune cells to fight cancer more effectively.
- ▪The research highlights the role of neutrophils in cancer resistance to immunotherapy, suggesting a new therapeutic approach.
2 outlets in our directory ran this story, first to last over 23 hours. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
- ▪ A Common Asthma Drug May Help the Immune System Fight Cancer Again — Discover Magazine
Live Science files mainly under science. We currently carry 137 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Live Science |
| Canonical URL | https://www.livescience.com/health/cancer/common-asthma-drug-helps-fight-hard-to-treat-cancers-including-aggressive-breast-cancers-early-study-finds |
| Publication time | Wed, 20 May 2026 17:23:54 +0000 |
| Retrieval time | 2026-05-20T17:30:03.038Z |
| Last seen | 2026-05-20T17:30:03.038Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | DAho-jJxE5kM · 2 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Health Viruses, Infections & Disease Cancer Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds Scientists found that blocking a protein best known for its role in asthma enhances cancer immunotherapy in preclinical models. By Marianne Guenot published 20 May 2026 in News When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Some cancers don't respond well to immunotherapy. An existing drug for asthma might help, research hints.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Live Science.
Discussion
0 commentsMore from Live Science
